Developing standard safety outcomes for COVID-19 vaccines
- PMID: 33888324
- PMCID: PMC7953438
- DOI: 10.1016/j.vaccine.2021.03.004
Developing standard safety outcomes for COVID-19 vaccines
Keywords: COVID-19 vaccines; Pharmacovigilance; Standards; Surveillance; Vaccine safety.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- Kim J.H., Marks F., Clemens J.D. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205–211. - PubMed
-
- Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf. 2003;12(4):335–340. - PubMed
-
- Rüggeberg J.U., Gold M.S., Bayas J.-M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675–5684. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
